Skip to main content
SpringerLink
Log in

Practice Guidelines for Transdermal Opioids in Malignant Pain

  • Therapy In Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Patients with moderate-to-severe malignancy-related pain require opioid pharmacotherapy. Many cancer patients continue to be prescribed subtherapeutic doses of pain medications resulting in undue suffering and diminished quality of life. Pain associated with malignancy and its treatment may exacerbate other symptoms associated with cancer, including nausea, fatigue, weakness, dyspnoea, constipation and impaired cognition. The choice of analgesic pharmacotherapy should be individualised and based on the intensity of pain reported by the patient, rather than its specific aetiology. When selecting pain management pharmacotherapy, the healthcare provider should consider the patient’s pain level, activity level and any comorbid illness. Intolerable adverse effects, ineffective pain relief or a change in the patient’s clinical status can dictate the need for a new pain management regimen.

Healthcare providers must be able to readily quantify the relative analgesic potency when converting from one opioid to another or from one route of administration to another. Transdermal formulations of fentanyl and buprenorphine are effective pharmacotherapy that can be safely used for cancer patients with pain. However, clinicians need to be cognisant that the US/UK manufacturer’s recommendations for equianalgesic dose administration of transdermal fentanyl may result in initial doses that produce subtherapeutic concentrations and unrelieved pain in some patients. A less conservative dose administration algorithm for transdermal fentanyl using a 2: 1 (mg/day of oral morphine: μg/h of transdermal fentanyl) conversion ratio that considers both a review of the literature and clinical experience should help clinicians individualise cancer pain pharmacotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Fig. 2

Similar content being viewed by others

References

  1. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330(9): 592–6

    Article  PubMed  CAS  Google Scholar 

  2. Coyle N, Adelhardt J, Foley KM, et al. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last 4 weeks of life. J Pain Symptom Manage 1990; 5(5): 83–93

    Article  PubMed  CAS  Google Scholar 

  3. Grond S, Zech D, Diefenbach C, et al. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994; 9(6): 372–82

    Article  PubMed  CAS  Google Scholar 

  4. Simmonds MA. Pharmacotherapeutic management of cancer pain: current practice. Semin Oncol 1997; 24 (5 Suppl. 16): S16.1-16.6

    PubMed  CAS  Google Scholar 

  5. Zhukovsky DS, Goroswski E, Hausdorff J,et al. Unmet analgesic needs in cancer patients. J Pain Symptom Manage 1995; 10(2): 113–9

    Article  PubMed  CAS  Google Scholar 

  6. Ferrer-Brechner T. The management of pain associated with malignancy. Semin Anesth 1985; 4: 313–22

    Google Scholar 

  7. Bucher JA, Trostle GB, Moore M. Family reports of cancer pain, pain relief, and prescription access. Cancer Pract 1999; 7(2): 71–7

    Article  PubMed  CAS  Google Scholar 

  8. Hanks GW. Cancer pain and the importance of its control. Anticancer Drugs 1995; 6 Suppl. 3: 14–7

    Article  PubMed  CAS  Google Scholar 

  9. World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: WHO, 1996

    Google Scholar 

  10. Zech DF, Grond SA, Lunch J,et al. Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63(1): 65–76

    Article  PubMed  CAS  Google Scholar 

  11. Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 1991; 42(2): 228–39

    Article  PubMed  CAS  Google Scholar 

  12. Zenz M, Strumpt M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992; 7(2): 69–77

    Article  PubMed  CAS  Google Scholar 

  13. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11(4): 203–17

    Article  PubMed  CAS  Google Scholar 

  14. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33(1): 11–23

    Article  PubMed  CAS  Google Scholar 

  15. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313(2): 84–95

    Article  PubMed  CAS  Google Scholar 

  16. Cherny NI, Portenoy RK. Cancer pain management: current strategy. Cancer 1993; 72 (11 Suppl.): 3393–415

    Article  PubMed  CAS  Google Scholar 

  17. American Pain Society. Principles of analgesic use in the treatment of acute pain and chronic pain. 5th ed. Chicago (IL): American Pain Society, 2004

    Google Scholar 

  18. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain. Cancer 1995; 76(11): 1283–93

    Article  PubMed  CAS  Google Scholar 

  19. Cherny NI, Portenoy RK. The management of cancer pain. CA Cancer J Clin 1994; 44(2): 262–303

    Google Scholar 

  20. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996; 335(15): 1124–32

    Article  PubMed  CAS  Google Scholar 

  21. Lawlor P, Turner K, Hanson J, et al. Dose ratio between morphine and hydromorhone in patients with cancer pain: a retrospective study. Pain 1997; 72(1-2): 79–85

    Article  PubMed  CAS  Google Scholar 

  22. Lawlor PG, Turner KS, Hanson J, et al. Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998; 82(6): 1167–73

    Article  PubMed  CAS  Google Scholar 

  23. Muijers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289–307

    Article  Google Scholar 

  24. Janssen Pharmaceutica. Duragesic (fentanyl transdermal system) full prescribing information. Titusville (NJ): Janssen Pharmaceutica, 2001

    Google Scholar 

  25. Kornick CA, Santiago-Palma J, Moryl N, et al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003; 26(13): 951–73

    Article  PubMed  CAS  Google Scholar 

  26. Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996; 64(3): 527–34

    Article  PubMed  CAS  Google Scholar 

  27. Breitbart W, Chandler S, Eagel H, et al. An alternative algorithm for dosing of transdermal fentanyl for cancer-related pain. Oncology (Huntingt) 2000 May; 14(5): 695–705

    CAS  Google Scholar 

  28. Higgs C, Vella-Brincat J. Withdrawal with transdermal fentanyl. J Pain Symptom Manage 1995; 10: 4–5

    Article  PubMed  CAS  Google Scholar 

  29. Zenz M, Donner B, Strumpt M. Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS). J Pain Symptom Manage 1994; 9(1): 54–5

    Article  PubMed  CAS  Google Scholar 

  30. Radbruch L, Eisner F. Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 2004; 53(1): 23–9

    Article  PubMed  CAS  Google Scholar 

  31. Zech D, Grond S, Lynch J, et al. Transdermal fentanyl and initial dose finding with patient controlled analgesia in cancer pain: a pilot study with 20 terminally ill cancer patients. Pain 1992; 50(3): 293–301

    Article  PubMed  CAS  Google Scholar 

  32. Kornick CA, Santiago-Palma J, Schulman G, et al. A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. Cancer 2003; 97: 3121–4

    Article  PubMed  Google Scholar 

  33. Kornick CA, Santiago-Palma J, Khojainova N, et al. A safe and effective method for converting patients from intravenous to transdermal fentanyl. Cancer 2001; 92: 3056–61

    Article  PubMed  CAS  Google Scholar 

  34. Cleary JF. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol 1997; 24 (5 Suppl. 16): 13–9

    Google Scholar 

  35. Payne R, Chandler S, Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anti Cancer Drugs 1995; 6(3): 50–3

    Article  PubMed  CAS  Google Scholar 

  36. The TTS Fentanyl Multicentre Study Group. Transdermal fentanyl in cancer pain. J Drug Dev 1994; 6(3): 93–7

    Google Scholar 

  37. Southam MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anticancer Drugs 1995; 6 Suppl. 3: 29–34

    Article  PubMed  CAS  Google Scholar 

  38. Portenoy RK, Southam M, Gupta SK. Transdermal fentanyl for cancer pain: repeated dose pharmacokinetics and efficacy. Anesthesiology 1993; 78(1): 36–43

    Article  PubMed  CAS  Google Scholar 

  39. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustainedrelease oral morphine in cancer pain: preference, efficacy, and quality of life. TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manag 1996; 13(5): 254–61

    Article  Google Scholar 

  40. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322(7295): 1154–8

    Article  PubMed  CAS  Google Scholar 

  41. Wong JO, Chiu GL, Tsaio CJ, et al. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997; 35(1): 25–32

    PubMed  CAS  Google Scholar 

  42. Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain 1998; 2(1): 53–62

    Article  PubMed  CAS  Google Scholar 

  43. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63(19): 1999–2010

    Article  PubMed  CAS  Google Scholar 

  44. Bohme K. Burprenorphine in a transdermal therapeutic system: a new option. Clin Rheumatol 2002; 21 Suppl. 1: S13–116

    PubMed  Google Scholar 

  45. Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl 2003; 133: 9–14

    PubMed  CAS  Google Scholar 

  46. Radbruch L, Vielvoye-Kerkmeer A. Buprenorphine TDS: the clinical development, rationale and results. Int J Clin Pract Suppl 2003; 133: 15–8

    PubMed  CAS  Google Scholar 

  47. Radbruch L. Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract Suppl 2003; 133: 19–24

    PubMed  CAS  Google Scholar 

  48. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003; 25(1): 150–68

    Article  PubMed  CAS  Google Scholar 

  49. Bohme K, Kikar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain: a randomized, double-blind, placebo-controlled study. Pain Clinic 2003; 15(2): 193–202

    Article  Google Scholar 

Download references

Acknowledgements

This article was supported by the Pharmacoeconomics & Pharmacoepidemiology Research Unit, Washington State University, Pullman, Washington, USA. The author reports no conflicts of interest.

Author information

Authors and Affiliations

  1. Pharmacoeconomics and Pharmacoepidemiology Research Unit, Washington State University, Pullman, Washington, USA

    Tracy L. Skaer

Authors
  1. Tracy L. Skaer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy L. Skaer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skaer, T.L. Practice Guidelines for Transdermal Opioids in Malignant Pain. Drugs 64, 2629–2638 (2004). https://doi.org/10.2165/00003495-200464230-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464230-00002

Keywords

Search

Navigation